看见一个 Expert Review of Anticancer Therapy。你们前面用依维莫斯,血、肝肾功能还好。下一步是否考虑索拉非尼+依维莫斯。供你参考。
- z6 q# n y" p6 r
, ]4 M$ ?4 `+ B& k4 @- i8 i A0 ?4 A4 E/ E+ p
Currently available feasibility data for possible combination strategies. . {) R$ k. D @: f& j& B
————————————————————————————————
) ~! s, {4 T8 p1 _$ n2 ECombination Feasibility according to preliminary data & `9 W: P/ Z2 c8 `2 g% w- S3 s
——————————————————————————————————0 ~( m9 r" O8 U5 f
Bevacizumab + sorafenib Yes, reduced dose 7 V! P- q6 k7 D
Bevacizumab + sunitinib† No ; v" r2 c: n8 X$ C% o
Bevacizumab + temsirolimus Yes ; r! W7 A. I9 y& r3 W$ O
Bevacizumab + everolimus Yes ! R% t4 g( _% p) i" N! O9 S' q
Sorafenib + sunitinib ?
3 @( q7 B/ {; T+ }3 S' @Sorafenib + temsirolimus Yes, reduced dose 4 a+ t5 D: _2 s
Sorafenib + everolimus Yes, reduced dose
2 H: k7 {, q7 y% X. u/ Q; P6 KSunitinib + temsirolimus† No
+ t2 Q, w7 Y' L7 k% p( oSunitinib + everolimus ? ( x( f8 P) t$ R) y# s
Temsirolimus + everolimus ? 4 J& [8 u- c6 w' r2 m0 {
————————————————————7 E7 l5 |+ c4 J( k1 D, y& G! f8 H
†Led to US FDA warning.
' x3 c4 Q- O! v) w. U?: As yet unattempted combination.
/ l. m \: X G& j: m' J$ w9 t |